Deal flow in­flux: Abing­worth's new $356M fund will help Big Phar­ma ex­pand drug la­bels

Abing­worth, a long-time life sci­ences in­vestor, has an­oth­er $356 mil­lion that it plans to spend co-de­vel­op­ing new med­i­cines through Phase III tri­als and help­ing Big Phar­ma com­pa­nies snag la­bel ex­pan­sions on al­ready ap­proved drugs.

The life sci­ences in­vestor dis­closed the new clin­i­cal co-de­vel­op­ment co-in­vest­ment fund on Mon­day morn­ing. With about 95% of the same in­vestors as its last fund in 2021, Abing­worth was able to quick­ly pull to­geth­er the fund over the sum­mer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER